TY - JOUR
T1 - A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point?
AU - Villani, Veronica
AU - Fabi, Alessandra
AU - Tanzilli, Antonio
AU - Pasqualetti, Francesco
AU - Lombardi, Giuseppe
AU - Vidiri, Antonello
AU - Gonnelli, Alessandra
AU - Molinari, Alessandro
AU - Cantarella, Martina
AU - Bellu, Luisa
AU - Terrenato, Irene
AU - Carosi, Mariantonia
AU - Maschio, Marta
AU - Telera, Stefano Maria
AU - Carapella, Carmine Maria
AU - Cognetti, Francesco
AU - Paiar, Fabiola
AU - Zagonel, Vittorina
AU - Pace, Andrea
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Aim: This multicenter, retrospective study evaluates the clinical benefit (CB) of bevacizumab, alone or in combination, in recurrent gliomas (RG). Patients & methods: The CB was measured as a reduction of corticosteroid dosage and an improvement ≥20 points in the Karnofsky Performance Status lasting ≥3 months. Results: We collected data of 197 RG patients. A CB was observed in 120, patients without significant differences between patients treated with bevacizumab alone or in combination. The rate of patients who achieved a CB and free from progression at 1 year was 21.5 versus 1.4% in patients who did not report CB. Conclusion: The majority of RG patients treated with bevacizumab reported CB. Moreover, patients with CB showed improved survival.
AB - Aim: This multicenter, retrospective study evaluates the clinical benefit (CB) of bevacizumab, alone or in combination, in recurrent gliomas (RG). Patients & methods: The CB was measured as a reduction of corticosteroid dosage and an improvement ≥20 points in the Karnofsky Performance Status lasting ≥3 months. Results: We collected data of 197 RG patients. A CB was observed in 120, patients without significant differences between patients treated with bevacizumab alone or in combination. The rate of patients who achieved a CB and free from progression at 1 year was 21.5 versus 1.4% in patients who did not report CB. Conclusion: The majority of RG patients treated with bevacizumab reported CB. Moreover, patients with CB showed improved survival.
KW - bevacizumab
KW - clinical benefit
KW - glioma
U2 - 10.2217/fon-2018-0826
DO - 10.2217/fon-2018-0826
M3 - Article
VL - 15
SP - 1717
EP - 1727
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 15
ER -